Dr. Wang is an established and well known expert in cardiovascular research and the
industry. Dr. Wang’ has major contributions to both pharmacology and device
therapies for cardiovascular diseases. He was the pioneer to introduce biotechnology
and biopharmaceuticals into China, funded and led two companies to manufacture
recombinant protein drugs and interventional cardiology devices.
Dr. Wang has numerous experience for filling IND and IDE in both USA and China.
Dr. Wang has served as a consultant to a number of the world’s largest pharmaceutical
companies, venture capital firms, start-up companies and consulting firms. He has
been working with Dr. Levin and Mr. Gelfand together as a team for more than 15
years, guided key animal experiments and first-in-man studies to prove the concept of
Ardian’s renal denervation therapy for hypertension, heart failure and other
Dr. Wang helped several US medical device companies to conduct their
first-in-human studies and efficacy studies in China.
His academic experiences and accomplishments are evidenced by more than 80
peer-reviewed articles, over 100 abstracts, grants, patents and many rewards.
His leadership in both academia and industry has been demonstrated by his
extraordinary carrier path: an associate professor at Columbia University, the Dean of
Medical School of Nanjing University, CEO/President of Vascore Medical Ltd, the
Director of Institute of Molecular and Experimental Therapeutics at East China
Normal University, and Associate Director of the Skirball Center for Cardiovascular
Research (A CRO) at Cardiovascular Research Foundation. Currently, he is the
Executive Vice President, Academy of Clinical Research and Translational Medicine,
Jiangsu Province Hospital, the largest hospital in Jiangsu Province with 2200 beds
and 3 million outpatients per year.
He has both clinical degree (MM, Hebei Medical College) and research degree (Ph.D,
physiology, New York Medica